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When to “CAP” off treatment  
for pneumonia
Is 5 days of antibiotic therapy really sufficient for adults 
hospitalized with community-acquired pneumonia? 
PRACTICE CHANGER
Prescribe 5 days of antibiotic treatment for 
inpatients with community-acquired pneu-
monia because it produces the same clinical 
success rates as longer treatment regimens, 
but is associated with fewer negative patient 
outcomes.1 
STRENGTH OF RECOMMENDATION 
B: Based on a single, good-quality random-
ized control trial.
Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in 
community-acquired pneumonia: a multicenter randomized clinical 
trial. JAMA Intern Med. 2016;176:1257-1265.1 
ILLUSTRATIVE CASE
A 65-year-old woman is admitted to your in-
patient service from your family health center. 
She is diagnosed with community-acquired 
pneumonia (CAP) based on a 5-day history of 
cough and fever and a positive chest x-ray. She 
now requires oxygen at rest. She has a past 
medical history of hypertension and diabetes, 
both of which have been controlled on oral 
medications. Antibiotic therapy is initiated for 
the treatment of the pneumonia, but what 
treatment duration is ideal? 
The World Health Organization esti-mates that pneumonia is the third most common cause of mortal-
ity worldwide, causing 3.2 million deaths per 
year.2 Appropriate prescribing of antibiotics is 
critical for the successful treatment of CAP. 
The Infectious Diseases Society of Amer-
ica (IDSA) and the American Thoracic So-
ciety (ATS) created consensus guidelines, 
published in 2007, for the treatment of CAP.3 
These guidelines recommend a minimum 
5-day course of antibiotics if the patient is 
clinically stable, which is defined as: afebrile 
for 48 hours, heart rate ≤100 beats/minute, 
respiratory rate ≤24 respirations/minute, 
systolic blood pressure ≥90 mm Hg, oxygen 
saturation ≥90%, normal mental status, and 
able to tolerate oral intake. Longer antibiotic 
treatment durations are recommended on an 
individualized basis, if, for example, the iso-
lated pathogen is not susceptible to the initial 
antibiotic or if the infection was caused by an 
extrapulmonary source. 
However, these recommendations are 
not routinely followed. Practitioners often 
make it their custom to prescribe longer 
courses of antibiotics.4 And yet we know that 
there are several reasons to consider shorter 
courses of antibiotics, including lower health 
care costs, fewer adverse effects, and lower 
rates of bacterial resistance.5-7 
❚ Two meta-analyses were performed 
to compare the safety and efficacy of short- 
(≤7 days) vs long-course (>7 days) antibiotic 
therapy in CAP.8,9 Both meta-analyses found 
no difference in efficacy or safety between 
shorter and longer courses of antibiotic treat-
ment regimens for CAP. Secondary outcomes 
noted a trend toward decreased antibiotic- 
associated adverse events with shorter courses 
of therapy.8,9 
While these meta-analyses supported 
shorter courses of antibiotics for CAP, there 
are limitations to the broad implementa-
tion of their findings. Studies included in 
these analyses utilized a variety of antibi-
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otic treatment regimens and longer courses 
(7 days vs 5 days) that are not recommended 
by the IDSA/ATS guidelines. Additionally, 
studies included both inpatient and out-
patient treatment groups, so findings may 
not apply to an exclusively inpatient CAP 
population.8,9 
This study sought to validate the 
IDSA/ATS guidelines recommending a 5-day 
course of antibiotics for hospitalized patients 
with CAP.1
STUDY SUMMARY
No differences in clinical outcomes  
between 5 days of Tx—and longer
This multicenter, double-blind, noninferior-
ity randomized trial compared short-term 
antibiotic treatment duration (5 days) to 
physician-discretion antibiotic treatment du-
ration among 312 patients ≥18 years of age 
admitted for CAP to one of 4 teaching hospi-
tals in Spain.1 Pneumonia was diagnosed on 
chest radiograph with at least one symptom: 
cough, fever, dyspnea, or chest pain. Patients 
were excluded if, among other things, they 
had an immunocompromising condition, 
lived in a nursing home, had a recent hospi-
tal stay, used antibiotics within the previous 
30 days, or had an uncommon pathogen, 
such as Pseudomonas aeruginosa or Staphy-
lococcus aureus.1
Patients were randomized after receiv-
ing a minimum of 5 days of antibiotics to an 
intervention group (where, if clinically stable, 
no further antibiotics were given) or a con-
trol group (where physicians determined an-
tibiotic duration).1 Primary outcomes were 
clinical success rate at Days 10 and 30 from 
admission, defined as resolution of signs and 
symptoms of CAP without further antibiotics, 
and improvement of CAP-related symptoms 
as determined by an 18-item CAP symptom 
questionnaire. This questionnaire was scored 
0 to 90, where higher scores indicated greater 
severity. Secondary outcomes included: du-
ration of antibiotic use, time to clinical im-
provement, mortality, hospital readmission, 
hospital length of stay, and CAP recurrence.1
A total of 312 patients were random-
ized with 162 patients in the interven-
tion group and 150 patients in the control 
group. The mean age of patients in the in-
tervention and control groups was 66.2 and 
64.7 years, respectively. Other baseline de-
mographics were similar between the groups. 
Nearly 80% of patients received quinolone 
treatment; <10% received a beta-lactam plus 
a macrolide.1
Clinical success rates were similar for 
the control and intervention groups, respec-
tively, at Day 10 (49% vs 56%; P=.18) and Day 
30 (89% vs 92%; P=.33). There was shorter 
median treatment duration with antibiotics 
in the intervention group compared with the 
control group (5 days vs 10 days; P<.001) and 
fewer 30-day hospital readmissions (1.4% vs 
6.6%; P=.02). There were no differences for 
other secondary outcomes.1
WHAT’S NEW
Clinical support for 2007 guidelines
This is the first study to clinically support 
the IDSA/ATS guidelines, which state that a 
5-day course of antibiotic therapy for hospi-
talized adults with CAP is effective and with-
out increased risk of adverse events.
CAVEATS
Generalizability to other meds 
and settings is unclear
This study focused on antibiotic duration 
for the treatment of CAP in hospitalized pa-
tients and mainly used quinolone antibiot-
ics. It remains unclear if duration of therapy 
is as effective in the outpatient setting or 
when using alternative antibiotic regimens. 
If patients continued to have symptoms 
(such as fever or low oxygen saturation on 
room air) after 5 days of antibiotic treatment, 
antibiotic treatment was continued in the 
study. Thus, patients in real life who continue 
to have symptoms may need individualized 
therapy and may require more than 5 days of 
antibiotics. 
CHALLENGES TO IMPLEMENTATION
Antibiotics end before clinical  
improvement occurs
This study noted an average of 12 days in 
both groups for patients to achieve clinical 
This is the first 
study to support 
the efficacy of 
the 5-day course 
of antibiotics 
for hospitalized 
CAP patients 
recommended 
by IDSA/ATS 
guidelines.
improvement, with upwards of 15 to 18 days 
for patients to return to normal activity. Pa-
tients and providers may be dissatisfied if the 
treatment course ends days before clinical 
improvement of symptoms. This may cause 
prescribers to lengthen the duration of anti-
biotic therapy inappropriately.               JFP
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